Anti-Idiotypic antibodies (anti-Id) are critical assay reagents used in PK/ADA assays for therapeutic biologics entering clinical trials. Ensuring the timely readiness of high-quality, assay-ready anti-Id is a top-priority task for all bioanalytical groups. In this webinar, the Abveris team will discuss how to de-risk anti-Id discovery in terms of screening platform and strategy selection. In this two-part webinar series, the following topics will be discussed: 1. Overview of screening technologies for anti-Id antibodies discovery 2. Do's and don'ts when planning and designing anti-Id discovery campaigns 3. Case studies of hybridoma-based and Beacon-based anti-Id campaigns targeting therapeutic biologics
